Nasdaq:TRVI – SPAC Feed

Nasdaq:TRVI
US89532M1018

April 16, 2026

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine…

By sf-admin